Global EditionASIA 中文雙語Fran?ais
Opinion
Home / Opinion / Opinion Line

Domestic COVID-19 drug raises hopes

China Daily | Updated: 2022-08-16 07:45
Share
Share - WeChat

The National Healthcare Security Administration has announced that all the medicines listed in the COVID-19 treatment plan can be paid for through the healthcare security fund.

On Aug 9, the National Health Commission said that Azvudine, a Chinese drug approved for treating COVID-19, was included in the COVID-19 treatment plan. This way, patients can get part of the cost paid for by the healthcare security fund.

A worker carries out sample testing in a medical company in Jiangsu province, on April 9, 2020. [Photo by Tang Dehong/for China Daily]

Society has long been expecting COVID-19 drugs to enter the market. China has long developed vaccines aimed at preventing the virus from infecting more people. The emerging drugs will further consolidate China's victory over the virus.

Azvudine, as the first domestically developed COVID-19 drug, has several advantages over foreign ones. It costs less than 300 yuan ($44.35) per bottle, which is largely affordable; it is an oral drug rather than injection, which makes it convenient to popularize it.

Besides, since Azvudine has long been used to fight AIDS and has recently been developed to fight COVID-19, its side-effects are known.

However, some believe that more clinical data is needed to prove its effectiveness. After all, Azvudine has not been tested yet for its effectiveness against COVID-19. That's possibly why the medicine has been "temporarily" included in the healthcare fund, creating room for a long-term decision to be taken after observation. In that way, the taxpayers' burden will not be that heavy.

More than two years into the COVID-19 pandemic, people are looking for an effective, cheap drug to counter it.

With the first domestically developed COVID-19 drug entering the market and getting included in the healthcare fund, there is more light at the end of the tunnel. Of course, one single drug is far from enough in fighting the pandemic, yet it highlights the spirit of doing scientific research for fighting the pandemic.

We look forward to more such drugs being developed to better serve the people in the fight against the pandemic.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 国产成人无码一区二区三区在线| 性欧美激情xxxd| 亚洲色大成网站www永久| 青草热在线精品视频99app| 国产麻豆精品高清在线播放| 中文字幕aⅴ在线视频| 最新浮力影院地址第一页| 亚洲色大成网站WWW尤物| 色偷偷一区二区无码视频| 国产精品99久久久久久董美香| www.99re| 无码人妻精品一区二区三区蜜桃 | 精品亚洲欧美无人区乱码| 国产成人3p视频免费观看| 91久久精品国产91久久性色tv | 大学生一级特黄的免费大片视频| 久久久久久久人妻无码中文字幕爆| 欧美人与动性行为另类| 人妻18毛片a级毛片免费看| 老师好长好大坐不下去| 国产成人精品无码免费看| 91福利视频免费观看| 好男人社区神马www在线影视| 久久久久久久综合狠狠综合| 欧美不卡在线视频| 亚洲精品国产v片在线观看| 精品卡2卡3卡4卡免费| 国产亚洲一区二区三区在线观看 | avtt天堂网手机资源| 在线成年视频免费观看| 一级一级特黄女人精品毛片| 无翼乌全彩里番蛇姬本子| 久草视频免费在线观看| 欧美国产日韩1区俺去了| 亚洲综合亚洲国产尤物| 精品亚洲一区二区三区在线观看| 国产三级在线观看完整版| 麻豆自创视频在线观看| 国产精品91在线播放| 91影院在线观看| 大陆三级特黄在线播放|